Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17546684 | 0.86 | MEN1 (0.61) | MEN1KMT2AMTNR1AMTNR1BLMNA | |
| SCHEMBL12300324 | 0.84 | MEN1 (0.45) | MEN1KMT2AMTNR1AMTNR1BLMNA | |
| SCHEMBL14878512 | 0.81 | TSHR (0.54) | KMT2AMTNR1AMTNR1BLMNAEPHX1 | |
| SCHEMBL13139407 | 0.81 | MEN1 (0.42) | MEN1KMT2AMTNR1AMTNR1BSTAT3 | |
| SCHEMBL8975691 | 0.80 | LMNA (0.46) | MEN1KMT2ALMNATSHRFBP1 | |
| SCHEMBL16556482 | 0.80 | MEN1 (0.54) | MEN1KMT2AMTNR1AMTNR1BLMNA | |
| Propanol SCHEMBL28627241 | 0.79 | MEN1 (0.52) | MEN1KMT2AMTNR1AMTNR1BLMNA | |
| SCHEMBL25970361 | 0.79 | TSHR (0.56) | MEN1KMT2AMTNR1AMTNR1BLMNA | |
| SCHEMBL17344727 | 0.79 | MEN1 (0.64) | MEN1KMT2AMTNR1AMTNR1BSTAT3 | |
| SCHEMBL27512309 | 0.77 | MEN1 (0.50) | MEN1KMT2AMTNR1AMTNR1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723509-B2 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |